LOS ANGELES--(BUSINESS WIRE)--Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company, announced today the signing of a license agreement with Outlook Pharmaceuticals, Inc., pursuant to which Auriga will have the exclusive rights to market and sell a new product indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in the United States. The new product combines one of the most frequently prescribed drug classes for this condition, in a unique dosage form previously not available.
